GPX4 and acute myeloid leukemia: They showed that concomitant inhibition of NRF2 using ML385 and of GPX4 using FIN56 or RSL3 synergistically eradicate AML through ferroptosis and apoptosis induction, suggesting that such a combination of therapy may represent a promising approach for the treatment of AML.